#Pitt_IDFall2025
Microevolutionary Models and Multi-omics Analysis Uncover The Cross-drug Resistance Characteristics of Capreomycin-selected #Mycobacterium #tuberculosis

www.sciencedirect.com/science/arti... #OpenAccess #TB #MicroSky #IDSky
November 19, 2025 at 11:51 PM
Community-acquired pneumonia is the leading infectious cause of morbidity and mortality globally.

Yet, there are several challenges associated with diagnosis, treatment, and long-term management of Community-acquired pneumonia.

Find out more in a new Seminar: tinyurl.com/hd2fwz7n
November 19, 2025 at 11:48 PM
Nontuberculous mycobacterial disease, predominantly caused by Mycobacterium avium complex (MAC), is an emerging global health concern. In OFID, authors investigated mortality and causes of death among patients with MAC isolates. https://bit.ly/43fZlRD
Mortality and Causes of Death in Patients with Mycobacterium avium Complex Isolates through 28 years
This nationwide study of 2,027 Danish patients with MAC isolates (1991-2018) revealed declining mortality. Age, male sex, DMAC, and comorbidities were asso
academic.oup.com
November 19, 2025 at 11:42 PM
The duration of infectiousness following pulmonary tuberculosis treatment initiation is uncertain.

In CID, authors assess whether a bundled intervention designed to decrease respiratory exposure was feasible and would reduce new tuberculosis infections in household contacts. https://bit.ly/4pK8R9b
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
AbstractBackground. The duration of infectiousness following pulmonary tuberculosis treatment initiation remains uncertain. We aimed to assess whether a bu
academic.oup.com
November 19, 2025 at 11:40 PM
This is an interesting finding and relevant after our recent classes on HIV PrEP therapy #PITT_IDFall2025
November 19, 2025 at 11:38 PM
November 19, 2025 at 11:36 PM
It is scary how frequently we encounter these extremely multi-drug resistant gram(-) organisms in routine clinical practice these days. This Providencia isolate is resistant to everything we tested it against (including salvage drugs not shown)
Antimicrobial resistance is a very real threat.
November 19, 2025 at 11:35 PM
I never tire of seeing the amazing success of HPV vaccination. We are seeing the elimination of a leading oncogenic virus pathogen in real time
(Source: GAVI)
www.gavi.org/vaccineswork...
November 19, 2025 at 11:35 PM
who.int WHO @who.int · Nov 19
Antibiotics don’t treat colds or flu.

These illnesses are usually caused by viruses and are mostly self-limiting, whereas antibiotics only work on bacteria.

✅ Let’s handle antibiotics with care and keep these life-saving medicines effective.

Learn more 👉bit.ly/AMRweek2025 #AntimicrobialResistance
November 19, 2025 at 11:34 PM
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006-2023

✅ Just Accepted
🔗 https://bit.ly/4oPBYae
November 19, 2025 at 11:34 PM
Emerging Risk of Campylobacter spp. Infection Associated with Anti-BCMA and Anti-GPRC5D Bispecific Antibodies

✅ Just Accepted
🔗 https://bit.ly/3LsCGeP
November 19, 2025 at 11:32 PM
New strategies for a vexing problem: injectables to the rescue for people with Multidrug-Resistant HIV

✅ Just Accepted
🔗 https://bit.ly/4ovrYCU
November 19, 2025 at 11:32 PM
European data reveal tetracycline resistance in 58% of #gonorrhea isolates

The finding suggests that doxycycline post-exposure prophylaxis is unlikely to reduce the region's rate of the sexually transmitted infection.

www.cidrap.umn.edu/g...
November 19, 2025 at 11:31 PM
Study of 2713 GN-BSI patients showed no change in 30-day mortality (10.7% vs 11.6%, p=0.467) but reduced MDR emergence (11% vs 6.5%, p<0.001) after implementing a management bundle. 📉💊##idsky
Implementation of a bundle for the management of patients with Gram-negative bloodstream infection: a pre-post quasi-experimental study
Lack of international guidelines for Gram-negative bloodstream infection (GN-BSI) management poses clinical challenges. We aimed to assess whether implementing a management bundle for GN-BSI patients affected mortality and/or emergence of multidrug resistance (MDR).MethodsSingle-center, quasi-experimental study including adult patients hospitalized with monomicrobial GN-BSI. In the pre-phase (2018-2019), no standardized protocol was used. In the post-phase (2022–2023), a bundle was applied including predefined rules for follow-up blood cultures (FU-BC), imaging, beta-lactam administration schedule and treatment duration. Primary endpoint was 30-day all-cause mortality; secondary endpoint was 30-day MDR-GN carriage or infection. Treatment-effect lasso models were used to estimate bundle impact.ResultsA total of 2713 patients were included: 1430 in the pre-phase and 1253 in the post-phase. FU-BCs were performed in 22.5% (n=322) vs 47% (n=589), p<0.001; imaging in 65.5% (n 936) vs 71.6% (n=897), p<0.001; median treatment duration was 10 days in both phases (p=0.625). Thirty-day mortality was 10.7% (n=153) vs 11.6% (n=143), p=0.467. New MDR carriage/infection was 140 (11.0%) vs 78 (6.5%), p<0.001. The bundle had no overall effect on 30-day mortality (ATE = 0.008, p=0.568), despite reduced mortality in BSIs due to carbapenem-resistant organisms (ATE = -0.074, p=0.197) the effect was not significant. MDR emergence was significantly reduced (ATE = -0.038, p=0.031) in both overall and high-risk populations.ConclusionsThe GN-BSI management bundle reduced MDR.
academic.oup.com
November 16, 2025 at 4:34 AM
November 16, 2025 at 4:33 AM
Microevolutionary Models and Multi-omics Analysis Uncover The Cross-drug Resistance Characteristics of Capreomycin-selected #Mycobacterium #tuberculosis

www.sciencedirect.com/science/arti... #OpenAccess #TB #MicroSky #IDSky
November 16, 2025 at 4:31 AM
How to approach a patient hospitalized for pneumonia who is not responding to treatment?
➡️Differential diagnosis
➡️Diagnostic workup

⚠️Escalating antibiotic treatment should not be the default option

doi.org/10.1007/s001...

#IDSky
November 16, 2025 at 4:28 AM